CI Investments Inc. lessened its position in Bristol-Myers Squibb Co (NYSE:BMY) by 13.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,075,680 shares of the biopharmaceutical company’s stock after selling 165,400 shares during the period. CI Investments Inc. owned about 0.07% of Bristol-Myers Squibb worth $68,564,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in BMY. Tradewinds Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares during the period. Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $111,000. Blue Chip Partners Inc. grew its position in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the period. BDO Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $123,000. Finally, Acrospire Investment Management LLC grew its position in shares of Bristol-Myers Squibb by 633.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,900 shares during the period. 69.67% of the stock is owned by institutional investors.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $102,800.00, a PE ratio of 24.73, a PEG ratio of 2.29 and a beta of 1.18. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s payout ratio is 62.99%.
A number of brokerages have recently commented on BMY. Barclays lifted their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Thursday, October 12th. Leerink Swann lifted their price objective on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Finally, Citigroup raised their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $65.05.
TRADEMARK VIOLATION WARNING: “CI Investments Inc. Has $68.56 Million Stake in Bristol-Myers Squibb Co (BMY)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/ci-investments-inc-has-68-56-million-stake-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.